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Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized
by multiple cellular and molecular dysfunctions of the innate and adaptive immunity.
Cytotoxic function of NK cells is compromised in patients with SLE. Herein, we
characterized the phenotypic alterations of SLE NK cells in a comprehensive manner to
further delineate the mechanisms underlying the cytotoxic dysfunction of SLE NK cells and
identify novel potential therapeutic targets. Therefore, we examined PBMC from SLE
patients and matched healthy controls by single-cell mass cytometry to assess the
phenotype of NK cells. In addition, we evaluated the cell function of NK cells (degranulation
and cytokine production) and the killing of B cell subpopulations in a B cell-NK cell in vitro
co-culture model. We found that SLE NK cells expressed higher levels of CD38 and were
not able to adequately upregulate SLAMF1 and SLAMF7 following activation. In addition,
ligation of SLAMF7 with elotuzumab or of CD38 with daratumumab on SLE NK cells
enhanced degranulation of both healthy and SLE NK cells and primed them to kill
circulating plasma cells in an in vitro co-culture system. Overall, our data indicated that
dysregulated expression of CD38, SLAMF1 and SLAMF7 on SLE NK cells is associated
with an altered interplay between SLE NK cells and plasma cells, thus suggesting their
contribution to the accumulation of (auto)antibody producing cells. Accordingly, targeting
SLAMF7 and CD38 may represent novel therapeutic approaches in SLE by enhancing NK
cell function and promoting elimination of circulating plasma cell.
Keywords: systemic lupus erythematosus (SLE), SLAMF, CD38, elotuzumab, daratumumab, NK cells,
CD150/SLAMF1 receptor, CD319/SLAMF7/CS1org March 2021 | Volume 12 | Article 6454781
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Systemic lupus erythematosus (SLE) is a multisystemic
autoimmune disease that mainly affects women of childbearing
age (1, 2). The pathogenesis remains elusive but includes
alterations of the immune system leading to the production of
autoreactive cells, autoantibodies and the formation of immune
complexes that ultimately damage organs (1, 3). Although
important progress was made over the last decades toward the
development of new treatments, management of SLE still relies on
the use of corticosteroids and immunosuppressive agents that
non-specifically target immune cells. Despite the well-established
importance of autoreactive B cells and autoantibody production in
the pathogenesis of the disease (1), treatments based on B cell
depletion have only been moderately successful so far (4). In this
context, understanding the role of other immune cells involved in
the pathogenesis of SLE and their link with antibody-producing
cells is taking a center stage in the development of new therapies.
Among the various cellular abnormalities that characterize SLE,
Natural Killer (NK) cells’ dysfunction has been supported by
various studies (5–8). NK cells are innate lymphocytes that play
a pivotal role in the immune surveillance (9), through the
recognition of healthy cells and the elimination of damaged or
infected cells. NK cells from SLE patients are reduced in number in
the peripheral blood, show impaired cytokine production upon
stimulation, reduced cytotoxicity, and defective antibody-
dependent cellular cytotoxicity (5). However, their exact role in
the pathogenesis of lupus remains elusive.
In the present study, we used single-cell mass cytometry to
perform a comprehensive phenotypic analysis of healthy and
SLE NK cells. We sought to identify how these alterations are
linked to the altered function of SLE NK cells and might
represent therapeutic options to treat SLE.MATERIALS AND METHODS
SLE Patients and Controls
SLE patients (N=44) were diagnosed according to the American
College of Rheumatology classification criteria and/or the
Systemic Lupus International Collaborating Clinics (SLICC)
criteria (10, 11), and were recruited from the Division of
Immunology and Allergy at Centre Hospitalier Universitaire
Vaudois (CHUV). All patients and controls were included in
the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
(12). Characteristics of the SLE patients included in this study are
provided in Table 1.
Age-, sex-, and ethnicity-matched healthy individuals were
chosen as controls. Disease activity score was measured using the
SLE Disease Activity Index (SLEDAI) scoring system. We
categorized patients into three groups of disease activity: inactive
(SLEDAI 0-3), moderate (SLEDAI 4-10) and active (SLEDAI >10).
Cell Isolation
Peripheral blood mononuclear cells (PBMC) were enriched by
density gradient centrifugation (FICOLL 400, Merck,
Switzerland). PBMC were cryopreserved in liquid nitrogen.Frontiers in Immunology | www.frontiersin.org 2Cell Culture
Cells were cultured in RPMI (Gibco; Life Technologies)
conta in ing 10% heat- inac t ivated FBS (Inst i tut de
Biotechnologies Jacques Boy), 100 IU/ml penicillin and 100 mg/
ml streptomycin (Bio Concept), hereafter referred to as complete
RPMI (cRPMI).
Antibodies
A complete list of mass cytometry, flow cytometry and purified
antibodies is provided in the Supplementary Table 1.
Some antibodies for the mass cytometry assay were
conjugated in our facility (MaxPar® X8 multimetal labeling kit,
Fludigm). Briefly, the MaxPar® polymer is loaded with the metal,
and then the antibody is partially denatured to allow its
conjugation to the polymer. Finally, the metal bound polymer
is conjugated to the antibody.
Mass Cytometry
Cryopreserved PBMC from SLE patients and matched healthy
controls were thawed, resuspended in cRPMI, stimulated with
cytokines or left unstimulated as mentioned in the figures. Cells
were stained for live/dead with cisplatin 50 µg (5min, room
temperature (RT)), barcoded with CD45-metal conjugated
antibodies (20min, RT) and then pooled. Next, cells were
incubated with metal conjugated antibody mix (20min, RT).
Cells were washed and fixed with 2.4% paraformaldehyde
(10 min; RT). Labeled samples were acquired on a Helios
Cytof System (Fluidigm). Flow cytometry standard (FCS) files
were normalized to EQ Four Element calibration beads using
CyTOF software. FCS files were debarcoded using Cytobank
(Beckman Coulter).
Mass Cytometry Data Analysis
Manual gating of FCS files was performed using FlowJo™
Software version 10.2 (Becton, Dickinson and Company;
2019). Data analysis was performed using R software (version
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Humbel et al. SLE NK Cells Function Restorationenvironment and single cell expression data were transformed
using hyperbolic inverse sine (with cofactor 5) (13).
Dimensionality reduction and 2-dimensional visualization were
done using the Barnes-Hut implementation of t-stochastic
neighboring embedding algorithm (Rtsne package).
Unsupervised clustering analysis on cell populations were
performed using self-organizing map in combination with
consensus clustering (FlowSOM package) in order to define 4
different clusters.
For the analysis of NK cells, we merged two experiments
designed with two different panels using CytofMerge (14) with
default settings. The CytofMerge methodology is based on the k-
nearest neighbor algorithm and a set of common markers in
order to impute the value of missing markers by taking the
median values of from the k most similar cells.
NK Cells Cytokine Production and
Degranulation
PBMCs were thawed and resuspended in cRPMI. For evaluation
of degranulation, NK cells were stimulated with IL-15 (50ng/ml),
IL-18 (50ng/ml) or a combination of IL-2 (50ng/ml) and IL-12
(20ng/ml). For evaluation of NK cell activation with monoclonal
antibodies cells were resuspended in cRPMI with IL-15 (1ng/ml).
Cells were then stimulated with or without cytokines (IL-2 and
IL-12, 50ng/ml and 20ng/ml respectively) with the following
antibodies: SLAMF1 A12 (5µg/ml), SLAMF7 162.1 (5µg/ml),
elotuzumab (0.1µg/ml), daratumumab (1µg/ml), elotuzumab
and daratumumab (0.1µg/ml and 1µg/ml respectively) and
incubated for either 6 or 18 hours at 37°C. BD GolgiPlug™,
BD GolgiStop™ and CD107a-PE were added 6h before readout.
After incubation, cells were stained with Live/Dead Aqua and
cell surface antibodies:CD3-BUV737, CD4-PB, CD8-BV605,
CD19-FITC, CD56-BUV395. After permeabilization with BD
Cytofix/Cytoperm™ kit, cells were stained with IFNg-AF700,
TNFa-APC. Finally, cells were fixed in BD CellFIX™ and stored
at 4°C until data acquisition on LSR Fortessa™ (BD Bioscience).
NK and B Cells Co-Culture
PBMC cells from HC were thawed and sequential positive
selection of CD19+ and CD56+ cells was performed (human
microbeads, Miltenyi positive selection kits) using the
AutoMACS® ProSeparator (Miltenyi Biotec). B cells were
stained with CFSE (LifeTech). All cells were resuspended in
cRPMI with IL-15 (1ng/ml).
NK cells were incubated for 30minutes at 37°C with the
following stimulation conditions: unstimulated, SLAMF1 A12
(5µg/ml), SLAMF7 162.1 (5µg/ml), elotuzumab (0.1µg/ml),
daratumumab (1µg/ml), elotuzumab and daratumumab
(0.1µg/ml and 1µg/ml respectively). After incubation NK cells
were washed and B cells were added (in cRPMI with IL-15) at a
2:1 ratio (NK min 500’000 cells, max 1Mio; B cells min 250’000,
max 500’000 cells) and incubated for 5.30hours. After incubation
cells were washed and stained with Live/Dead Aqua, CD56-
BUV395, CD20-PB, CD21-AF700, CD27-PeCy7, CD38-ECD,
SLAMF7-PE. Finally, cells were fixed in CellFIX™ and stored
at 4°C until data acquisition on a LSR Fortessa™.Frontiers in Immunology | www.frontiersin.org 3Depletion Assay
PBMCs were thawed and CD3 negative cells were isolated
(EasySep™ Human CD3 Positive Selection Kit II, StemCell
Technologies). Cells were resuspended in cRPMI with IL-15
(1ng/ml), and the following stimulation conditions were added:
not stimulated, SLAMF1 (5µg/ml) with cytokines (IL-2 (50ng/
ml) and IL-12 (20ng/ml)), elotuzumab (0.1µg/ml) with
cytokines, daratumumab (1µg/ml) with cytokines and HLA-DR
(0.005µg/ml) with cytokines. CD3 negative cells were then
incubated for either 6 or 18 hours at 37°C. After incubation,
cells were stained extracellularly with Live/Dead Aqua, CD3-
BUV737, CD19-FITC, CD20-PB, CD27-AF700, CD38-ECD,
CD56-BUV395, SLAMF7-PE. Cells were then washed in
annexin buffer (10X Annexin V Buffer, BD Pharmingen) and
stained with Annexin V-APC. Cells were stored at 4°C until data
acquisition on LSR Fortessa™, for maximum 2h.
Statistics
Statistical analysis were performed using GraphPad Prism
(version 8). Specifications of tests exploited and sample size for
each experiment are mentioned in the figure descriptions. In a
general manner, Mann-Whitney test was used for comparison
between two groups with non-normal distribution (normality
was assessed with Shapiro-Wilk test). Kruskal-Wallis test was
used for the comparison of multiple groups with non-normal
distribution and p-values were adjusted for multiple tests using
Dunn’s method. One-way ANOVA was used for the comparison
of multiple groups with normal distribution and p-values were
adjusted for multiple tests using Sidak’s method. Two-way
ANOVA was exploited for the comparison of multiple groups
and p-values were adjusted for multiple tests using Sidak’s
method. Two-way ANOVA was exploited for multiple
comparisons within a group and p-values were adjusted for
multiple tests using Tukey’s method. A p-value lower than 0.05
was considered significant.
Study Approval
Informed written consent was obtained from all participants
prior to inclusion and the study was approved by the
Institutional Review Board (SwissEthics 2017-01434), in
compliance with the Declaration of Helsinki.RESULTS
NK Cells Are Reduced in Numbers and
Their Function Is Impaired in SLE Patients
Aspreviously reported, SLEpatientsdisplay a significantdecrease in
the absolute numbers of NK cells compared to sex-, age- and
ethnicity- matched healthy controls (HC; Figures 1A, D).
Percentage and/or absolute numbers of CD56+CD16+ and
CD56hiCD16- NK cell subsets are reduced in SLE patients
(Figures 1B, D). Decreased NK cell numbers correlate with
disease activity, as patients with higher disease activity display a
more profound reduction inNKcell numbers compared to patients
with inactive disease and HC (Figure 1C).March 2021 | Volume 12 | Article 645478
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NK cells with a combination of IL-2 and IL-12, which promoted
the production of IFNg and TNFa by SLE NK cells (Figure 1E),
although significantly less compared to HC (Figure 1E). In
response to IL-15 and IL-18, the degranulation of SLE NK cells
is impaired compared to HC, as illustrated by the reduced
frequency of CD107a+ NK cells in SLE patients (Figure 1F).
Stimulation with IL-2 and IL-12 provided a strong enough
stimulation to activate SLE NK cells degranulation as
effectively as in HC (Figure 1F). Collectively, our data indicates
that SLE NK cells display impaired cytokine productionFrontiers in Immunology | www.frontiersin.org 4and reduced degranulation in response to activation with
different cytokines.
Phenotypic Alterations of SLE NK Cells
We exploited single-cell mass cytometry to decipher the
extracellular phenotype of SLE NK cells. Our panels include
lineage markers for T cells, B cells, NK cells, monocytes and
dendritic cells. The gating strategy is presented in Supplementary
Figure 1. Various markers that characterize NK cells
subpopulations, as well as markers that have been shown to be





FIGURE 1 | NK cells are decreased and dysfunctional in patients with SLE. (A) Total NK cells and (B) CD56+CD16+ and CD56hiCD16- NK subpopulations in SLE
patients and HC are shown as absolute number (HC=17, SLE=27; Mann-Whitney Test) and percentage of total lymphocytes (HC=31, SLE=31; Mann-Whitney Test).
(C) Total NK cells and CD56+CD16+ absolute number according to SLE disease activity (HC=17, Inactive=15, Moderate=6, Active=4; Kruskal-Wallis Test with
Dunn’s multiple comparison test). (D) Representative dot-plot of NK cells (left) and subpopulations (right) staining gated on live CD45+CD14-CD7+CD20-CD19-
cells. The percentages of NK, CD56+CD16+ and CD56hiCD16- refer to % of total lymphocyte count. (E) Cumulative results and representative dot-plot showing NK
cell cytokines production in SLE and HC after overnight stimulation (IFNg HC=12, SLE=12; TNFa HC=13, SLE=13; mixed-effects analysis and two-way ANOVA with
Sidak’s multiple comparison test). (F) Cumulative results and dot-plot showing NK cell degranulation (CD107a+ cells) after overnight stimulation in SLE and HC
(HC=11, SLE=11; two-way ANOVA and Sidak’s multiple comparison test). Data represent mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). HC, healthy controls.March 2021 | Volume 12 | Article 645478
Humbel et al. SLE NK Cells Function RestorationThese include CD25, CD38, PD-1, activation receptors (NKp46,
NKG2D, DNAM-1), inhibitory receptor (NKG2A. KIR2DL,
KIR3DL) and receptors belonging to the SLAMF family,
including SLAMF1 (CD150), SLAMF2 (CD48), SLAMF3
(CD229), SLAMF4 (CD244, 2B4), SLAMF5 (CD84), SLAMF6
(CD353, NTB-A) and SLAMF7 (CD319, CRACC, CS-1).
Our data indicates that CD38 is expressed at a higher level in
total SLE NK cells (CD3-CD14-CD7+CD19-CD56+) (Figure 2A;
Supplementary Figure 2A). This difference is independent of
disease activity (Figure 2B) and is also observed in CD56+CD16+
and CD56hiCD16- NK subsets (Figures 2C, D). Similar resultsFrontiers in Immunology | www.frontiersin.org 5were found for treatment-naïve SLE patients (Supplementary
Figure 2B), suggesting that this alteration is not drug-related. We
applied clustering analysis on pre-gatedNK cells and identified four
cell clusters (Figure 2E) that do not differ in frequency between HC
and SLE, indicating that there is no NK subpopulation that is
characteristic of SLE patients and could be used as a biomarker.
Interestingly, we observed that cluster 2 has a CXCR5 expressing
subpopulation and cluster 4 one expressing KIR3DL1, which are
only present in SLE patients (Figure 2E). Further research is





FIGURE 2 | Analysis of NK cell surface markers in SLE patients and controls by single-cell mass cytometry. (A) Percentage of NK cells expressing the indicated cell
surface markers in HC and SLE (HC=33, SLE=33; two-way ANOVA and Sidak’s multiple comparison test). (B) Frequency of CD38+ NK cells in SLE patients
according to the SLE disease activity (HC=31, Inactive=16, Moderate=7, Active=7; Kruskal-Wallis Test with Dunn’s multiple comparison test). (C) Representative
t-SNE analysis showing the expression of CD38 on SLE and HC NK cells (down-sample HC=30’000 cells, SLE=30’000 cells; blue: CD56+CD16+ NK cells; red:
CD56CD16hi NK cells). (D) Cumulative results showing the expression (mean intensity) of CD38 on total NK, CD56+CD16+ and CD56hiCD16- NK cells (HC=31,
SLE=31; Mann-Whitney test). (E) t-SNE analysis (down-sample HC=10’000 cells, SLE=10’000 cells) and heatmap showing NK cell clusters in HC and SLE patients.
Data represent mean ± SEM (*P < 0.05, ***P < 0.001). HC, healthy controls.March 2021 | Volume 12 | Article 645478
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SLAMF1 and SLAMF7 in Response to
Cytokine Stimulation
Since the response of SLE NK cells to cytokine stimulation is
impaired and considering that the function of NK cells relies on
their extracellular phenotype (9), we examined the expression of
NK cells surface receptors following stimulation with IL-2 and IL-
12 for up to 48h in SLE patients and matched HC. We observed a
marked upregulation of SLAMF1 and SLAMF7 on NK cells from
HC, 11-fold and 9-fold respectively at 48h of cytokines stimulation,
compared to unstimulated cells (Figure 3A). Interestingly, PD-1
also shows a 5.6-fold increase at 48h of stimulation (Figure 3A).Frontiers in Immunology | www.frontiersin.org 6Of note, CD38 is not significantly upregulated after NK cells are
activated with cytokines (Figure 3A). However, NK cells from SLE
patients failed to upregulate certain cell surface receptors to the
same extent as HC (Figures 3B, C; Supplementary Figure 3).
More specifically, although SLAMF1 expression is also upregulated
on SLE NK cells upon cytokine stimulation, the upregulation is less
prominent than that observed in HC (Figures 3B, C). Similarly,
NK cells from SLE patients fail to upregulate SLAMF7 and PD-1 to
the same extent as HC (Figures 3B, C; Supplementary Figure 3).
Overall, our data shows that NK cells from SLE patients fail to




FIGURE 3 | SLAMF1 and SLAMF7 fail to be properly upregulated on the surface of SLE NK cells after activation with cytokines. (A) Expression of surface markers
after 24h and 48h of stimulation with cytokines on healthy NK cells, standardized to their level of expression on unstimulated cells (HC=23, SLE=23; Mixed-effects
analysis with Sidak’s multiple comparison test). (B) t-SNE presentation of the expression level of SLAMF1 and SLAMF7 in HC and SLE patients before and after
stimulation with cytokines (down-sample HC=12’000 cells, SLE=12’000 cells). (C) Comparison of expression of NK cell surface markers after 24h and 48h of
stimulation with cytokines between HC and SLE patients as mean intensity (above) and frequency (below) (HC=14, SLE=14; two-way ANOVA and Sidak’s multiple
comparison). Data represent mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). HC, healthy controls.March 2021 | Volume 12 | Article 645478
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Specific Monoclonal Antibodies (mAb)
Enhances the Function of Healthy and
SLE NK Cells
We investigated how the engagement of SLAMF1, SLAMF7 and
CD38 with mAb influences NK cell function, by examining the
production of cytokines, degranulation and cell viability after 6h
and 18h. Ligation with elotuzumab, a humanized anti-SLAMF7
mAb approved to treat relapsing multiple myeloma (15),
promotes NK cells degranulation and IFNg production after
18h, whereas no significant NK cells activation was observed at
6h of stimulation in HC (Figure 4A). Another clone of anti-
SLAMF7 mAb (clone 162.1), which has been shown to enhance
the cytotoxic response of SLE CD8+ T cells in response to viral
antigen (16), did not produce any significant effect on NK cells
degranulation (Figure 4A). NK cells stimulation with
daratumumab, a mAb that agonizes CD38, strongly enhanced
NK cells degranulation, IFNg and TNFa production (Figure
4A). Interestingly, in healthy controls daratumumab effectively
promotes NK cell degranulation and production of IFNg and
TNFa after 6h of stimulation, whereas elotuzumab takes longer
to activate NK cells (18h) and only promotes degranulation andFrontiers in Immunology | www.frontiersin.org 7production of IFNg, but not TNFa. Stimulation of NK cells with
anti-SLAMF1 mAb (clone A12) did not result in any effect on
degranulation or cytokine production (Figure 4A).
Next, we examined the effect of SLAMF7 ligation with
elotuzumab and of CD38 with daratumumab on NK cells from
SLE patients. Based on our results from healthy controls, we used
anti-SLAMF1 (clone A12) as negative control. We observed that
in SLE NK cells both daratumumab and elotuzumab promote
degranulation, after 6h and 18h respectively, to the same extent
as in HC (Figures 4B, C). However, compared to results
obtained in healthy controls, daratumumab and elotuzumab do
not promote cytokine production by SLE NK cells
(Supplementary Figure 4A). Furthermore, the magnitude of
degranulation at 18h is, for both HC and SLE NK cells, more
prominent following ligation with daratumumab (6-fold)
compared to elotuzumab (4-fold) (Figure 4C). In addition, we
examined NK cells viability after stimulation with elotuzumab
and daratumumab. Both antibodies lead to a slight increase in
mortality of NK cells compared to the control condition
(Supplementary Figure 4B). Eventually, we examined the
effect of elotuzumab and daratumumab on other lymphocyte
subsets and observed no effect on the viability or activation ofA
B C
FIGURE 4 | Engagement of SLAMF7 and CD38 with specific mAb enhances the function of healthy and SLE NK cells. (A) Degranulation (CD107a) and production
of cytokines (IFNg and TNFa) in NK cells of healthy controls after stimulation with daratumumab (N=14) and elotuzumab (N=12, Mixed-effect analysis with Tukey’s
multiple comparison test). (B) Degranulation (CD107a+) in NK cells of SLE patients after stimulation with daratumumab (6h N=15, 18h N=10) and elotuzumab (6h
N=14, 18h N=10; two-way ANOVA analysis and Sidak’s multiple comparison test). (C) Fold change of CD107a compared to control after 6h or 18h stimulation with
elotuzumab or daratumumab in HC and SLE patients (HC 6h=9, HC 18h=10, SLE 6h=15, SLE 18h=10; mixed-effect analysis with Sidak’s multiple comparison).
Data represent mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). HC, healthy controls.March 2021 | Volume 12 | Article 645478
Humbel et al. SLE NK Cells Function RestorationCD4+, CD8+ T cells and B cells (Supplementary Figures 5
and 6).
Altogether, our data shows that elotuzumab and daratumumab
specifically activate SLE NK cells by promoting their
cytotoxic activity.
Expression of CD38, SLAMF1,
and SLAMF7 Characterizes SLE
Circulating Plasma Cells
The above-mentioned cell surface receptors are important in
cell-to-cell contact. Therefore, to understand their relevance for
the pathophysiology of SLE, we investigated their expression on
other major lymphocyte populations. We manually gated on
CD4+, CD8+, DN T cells (CD4- CD8- double negative T cells), B
cells and NK cell. We then exploited t-SNE analysis to visualize
the expression of CD38, SLAMF1 and SLAMF7 on these cell
populations (Figure 5A) and quantified their relative expression
levels in SLE patients and HC (Figure 5B).
Other than NK cells, our data indicates that all three receptors
are expressed at higher levels on SLE B cells compared to HC.
CD38 expression did not show any difference in its expression
between SLE and HC in any other lymphocyte population
included in this study (Figures 5A, B). The expression of
SLAMF1 is significantly higher on B cells and on CD4+ T cells
from SLE patients as previously described (17). In addition, our
data shows that SLAMF7 is increased on total B cells from SLE
patients, despite a low expression level compared to other
lymphocytes such as NK cells, CD8+ and DN T cells. We further
examined the expression of these receptors on B cell
subpopulations. A t-SNE analysis of naïve B cells (CD19+ CD27-
IgD+), non-naïve B cells (CD19+ which are not CD27- IgD+) and
circulating plasma cells (CD19+ CD20- CD27+ CD38+ IgD-),
showed that all three molecules are expressed at a higher level on
circulating plasma cells compared to other B cell subpopulations
(Figures 5C, D). Moreover, the level of expression of all the three
receptors is increased in SLE circulating plasma cells compared to
HC, suggesting that these molecules could contribute to the
dysfunction of SLE B cells.
Activation of SLE NK Cells With mAb
Directed Against CD38 and SLAMF7
Promotes the Killing of Peripheral
Blood Plasma Cells
We evaluated whether the activation of NK cells can promote the
killing of SLE peripheral blood plasma cells. We generated a NK-
B cell in vitro co-culture system, in which we pre-stimulated NK
cells of HC with elotuzumab or daratumumab, then co-cultured
them with autologous B cells and measured the mortality of B
cell subsets.
First, our data shows that elotuzumab (18h) and
daratumumab (6h) can efficiently kill circulating plasma cells,
leading to 2.1 and 2.7 fold more dead cells compared to negative
control (SLAMF1 stimulation) respectively (Figure 6A).
Furthermore, when NK cells are activated with either mAb
they kill circulating plasma cells specifically, sparing other B
cell subpopulations, such as naïve, activated, resting and tissueFrontiers in Immunology | www.frontiersin.org 8like memory cells (Figure 6A). Second, we observed that the
presence of NK cells is necessary to achieve significant killing of
circulating plasma cells, although both mAb alone have a minor
impact on circulating plasma cell mortality (Figure 6B).
Due to the restrictions in the SLE sample size that we can
obtain, we could not repeat this assay in SLE patients.
Accordingly, we isolated CD3- cells and stimulated them with
mAb. We observed that at 6h, treatment with daratumumab
significantly killed circulating plasma cells of SLE patients to the
same extent as in the matched HC (Figure 6C). In conclusion,
our results strongly suggest that these mAb act through the
activation of SLE NK cells and effectively kill SLE circulating
plasma cells.DISCUSSION
We exploited single-cell mass cytometry to decipher the
phenotypic alterations that characterize SLE NK cells. Our data
identified CD38 as being highly expressed on SLE NK cells
compared to HC. Moreover, we observed that SLE NK cells
fail to properly upregulate SLAMF1 and SLAMF7 when activated
with cytokines; two receptors that play an important role in cell-
to-cell interaction. We showed that these three receptors are also
highly expressed on SLE peripheral blood plasma cells, a cell
population that contributes to the production of autoantibodies
in SLE. In addition, we demonstrated that mAb directed against
CD38 and SLAMF7 receptors enhance the degranulation of SLE
NK cells and selectively promote the killing of peripheral blood
plasma cells. Overall, our data suggests that the dysregulation of
SLAMF1 and SLAMF7 on the surface of SLE NK cells contribute
to their dysfunction and might impair their interaction with
plasma cells, resulting in an accumulation of autoantibody
producing cells. Additionally, targeting NK cells with activating
mAb may represent an attractive direction to eliminate
autoantibody-producing cells in SLE.
SLAMF1 and SLAMF7 belong to the signaling lymphocytic
activation molecule family receptors. A unique feature of these two
SLAMF members is that they act as self-ligand (18). The
involvement of SLAMF molecules in SLE pathogenesis has been
repeatedly reported (16–24) as well as their importance in NK cells
activation and interaction with other cell types (25, 26). SLAMF1
has been reported to be expressed at a higher level on SLE B cells
and CD4+ T cells compared to their healthy counterparts and its
importance for SLE B cell function was previously reported (26).
However, its potential role on SLE NK cells was not previously
described. SLAMF7 has been shown to be highly expressed by
cytotoxic cells and plasma cells. SLAMF7 displays an altered
expression, function and/or regulation on SLE NK cells and
CD8+ T cells (16, 19, 22), supporting a role of this molecule in
SLE pathogenesis. The importance of SLAMF7 was described in
multiple myeloma, where elotuzumab was approved to treat
disease relapse (15). The binding of elotuzumab contributes to
the elimination of myeloma cells, through various mechanisms
including the activation of NK cells cytotoxic response and
antibody dependent cell-mediated cytotoxicity (27). A previousMarch 2021 | Volume 12 | Article 645478
Humbel et al. SLE NK Cells Function Restorationstudy has shown that the ligation of SLAMF7 in SLE promotes the
degranulation of CD8+ T cells in response to viral antigens,
therefore empowering the antiviral response that is
compromised in patients with SLE (16), highlighting the
potential therapeutic benefit of targeting SLAMF7.
CD38 is a surface glycoprotein with ectoenzymatic functions
and is expressed at high levels on plasma cells. Like SLAMF7,
CD38 has been identified as a target for mAb to eliminate
myeloma cells in patients with relapsing multiple myeloma
with the use of anti-CD38 daratumumab (28). A recent reportFrontiers in Immunology | www.frontiersin.org 9has shown that daratumumab represents a potential therapeutic
approach to eliminate antibody-producing plasma cells in SLE
patients (29). Furthermore, it has been shown to ameliorate
clinical manifestations and to eliminate antibody producing
plasma cells in two patients with refractory SLE (30). A subset
of SLE patients who are highly susceptible to infections, exhibit
an altered CD8+ T cells cytotoxic response and express a high
level of CD38 on their surface (31), thus further underlining the
potential benefits of targeting CD38. Our data stresses a
preponderant role of NK cells in the process leading to plasmaA B
DC
FIGURE 5 | Expression of CD38, SLAMF1 and SLAMF7 characterizes SLE circulating plasma cells. (A) t-SNE presentation of the expression level of CD38,
SLAMF1 and SLAMF7 in main lymphocyte populations for HC and SLE patients (down-sample HC=100’000 cells and SLE=100’000 cells). (B) Comparison of mean
expression level of CD38, SLAMF1 and SLAMF7 between HC and SLE patients in main lymphocyte populations (HC and SLE=31; two-way ANOVA with Sidak’s
multiple comparison test). (C) t-SNE presentation of the expression level of CD38, SLAMF1 and SLAMF7 in B cell subpopulations for HC and SLE patients (down-
sample N=10’000 cells per subpopulation HC and SLE=26). (D) Comparison of the mean expression level of CD38, SLAMF1 and SLAMF7 between HC and SLE
patients in B cell sub-populations (HC=31, SLE =31; two-way ANOVA with Sidak’s multiple comparison test, SM, switch memory; NSM, non switch memory;
DN, double negative). Data represent mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). HC, healthy controls.March 2021 | Volume 12 | Article 645478
Humbel et al. SLE NK Cells Function Restorationcell depletion by daratumumab, as stimulation of isolated NK
cells with daratumumab is sufficient to promote the killing of
circulating plasma cells in culture, whilst the sole exposure of B
cells to the drug isn’t.
As previously reported, PD-1 is also upregulated on NK cells
in response to inflammatory cytokines (32). This increase is
significantly altered in SLE NK cells and likely reflects SLE NK
cells compromised activation status. Further investigation is
warranted on this aspect.
Our study reveals interesting differences between daratumumab
and elotuzumab. Elotuzumab promotes degranulation of NK cells
and IFNg production, but not the production of TNFa by NK cells.
Since elevated TNFa levels have been described in SLE patients
and may contribute to the pathogenesis of organ damage (33), this
property could be of interest if elotuzumab was to be considered as
a therapeutic option in SLE. On the other hand, SLE NK cell
degranulation and elimination of antibody-producing cells in vitro
is more robust when NK cells are activated with daratumumab
compared to elotuzumab.
Our study has several limitations. First, the use of single-cell
mass cytometry limits the identification of cell surface receptors
to the antibodies included in our panels. Compared to RNA seq,
this method monitors fewer targets but directly identifies cell
surface proteins that can be targeted by therapeutic mAb.
Second, further experiments are warranted to identify theFrontiers in Immunology | www.frontiersin.org 10individual implications of the three cell surface markers
evaluated in this study in the interaction between NK cells and
circulating plasma cells. So far, this aspect remains unexplored
due to the limited number of circulating plasma cells available
from the peripheral blood of patients and controls. We are
working on plasma cell line culture system that will allow to
individually silence each receptor. Finally, examination of
secondary lymphoid organ and bone marrow aspirations
would allow examination of B cells during their maturation
process and long-lived plasma cells. However, these tissues are
difficult to obtain.
In conclusion, the failure of SLAMF1 and SLAMF7 regulation
on SLE NK cells might contribute to an impaired interaction
between NK cells and plasma cells. This might lead to the
accumulation of antibody producing plasma cells that
characterizes SLE. From this point of view, restoration of NK cell
cytotoxicity may contribute to the elimination of SLE plasma cells.
Targeting SLAMF7 with elotuzumab and CD38 with
daratumumab contributes to the elimination of antibody
producing cells in vitro and this elimination occurs, at least in
part, through the restoration of SLE NK cells degranulation.
Because both elotuzumab and daratumumab are safe when used
to treat multiple myeloma and appear to be well-tolerated when
administrated to SLE patients, their utilization should be evaluated
in controlled studies to assess their efficacy to treat SLE.A
B C
FIGURE 6 | Activation of SLE NK cells with mAb directed against CD38 and SLAMF7 promotes the killing of peripheral blood plasma cells. (A) Frequency of dead
cells in a NK-B cell co-culture system after 6h (N=14) and 18h (N=16) following stimulation with SLAMF1, elotuzumab or daratumumab (one-way ANOVA with
Tukey’s multiple comparison test). (B) Fold increase of dead circulating plasma cells following stimulation with daratumumab 6h (N=12) or elotuzumab 18h (N=7) in
either B cells alone or B cells co-cultured with pre-stimulated NK cells (one-way ANOVA with Sidak’s multiple comparison test) (C) Ratio of dead cells over control
condition after 6h stimulation with elotuzumab or daratumumab in HC and SLE patients (HC=8, SLE=8; two-way ANOVA, Sidak’s multiple comparison test). Data
represent mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). HC=healthy controls.March 2021 | Volume 12 | Article 645478
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